Novigenix is a precision medicine company that specializes in ImmunoTranscriptomic solutions.
NOVIGENIX has raised $1.9M in total funding. The most recent round was Grant. The last funding was announced in March 2025.
NOVIGENIX's investors include European Union, Eurostars, Innovative Health Initiative.
NOVIGENIX is headquartered in Epalinges, Switzerland.
Novigenix is a precision medicine company that specializes in ImmunoTranscriptomic solutions.
NOVIGENIX is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NOVIGENIX — Funding & Investors." VCBacked, March 31, 2025, https://www.vcbacked.co/company/novigenix. Accessed July 20, 2026.
VCBacked. (2025). NOVIGENIX — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/novigenix
{{cite web |title=NOVIGENIX — Funding & Investors |url=https://www.vcbacked.co/company/novigenix |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated